Mga Batayang Estadistika
| LEI | 529900A4S2D4OGOJLL02 |
| CIK | 944809 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to OPKO Health, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| July 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025. |
|
| July 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2025 OPKO Health, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33528 75-2402409 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| July 31, 2025 |
Exhibit 99.1 OPKO Health Reports Second Quarter 2025 Business Highlights and Financial Results Conference call begins at 4:30 p.m. Eastern time today MIAMI, July 31, 2025 – OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and six months ended June 30, 2025. Highlights from the second quarter of 2025 and recent weeks include the following: • Merck adva |
|
| May 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 27, 2025 OPKO Health, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33528 75-2402409 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| May 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025. |
|
| May 1, 2025 |
Exhibit 10.1 EXCHANGE AGREEMENT This Exchange Agreement (this “Agreement”) is made and entered into as of [●], 2025, by and between OPKO Health, Inc., a Delaware corporation (the “Company”), and the noteholder identified on Schedule A (the “Noteholder”). The Company and the Noteholder are sometimes collectively referred to herein as the “Parties” and each individually as a “Party.” WHEREAS, the No |
|
| April 30, 2025 |
Exhibit 99.1 OPKO Health Reports First Quarter 2025 Business Highlights and Financial Results Conference call begins at 4:30 p.m. Eastern time today MIAMI (April 30, 2025) – OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended March 31, 2025. Highlights from the first quarter of 2025 and recent weeks include the following: ● Signed definitive |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2025 OPKO Health, Inc. |
|
| April 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 23, 2025 OPKO Health, Inc. |
|
| April 1, 2025 |
Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2025 OPKO Health, Inc. |
|
| March 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2025 OPKO Health, Inc. |
|
| March 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K/A Amendment No. 1 -12-31FY2024 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K/A Amendment No. |
|
| March 21, 2025 |
OPKO Health, Inc. Insider Trading Policy. EX-19.1 2 ex792993.htm EXHIBIT 19.1 Exhibit 19.1 OPKO HEALTH, INC. INSIDER TRADING POLICY (Revised July 22, 2008) This Insider Trading Policy provides guidelines to all personnel (“Restricted Persons”), including employees (both domestic and international), directors and officers, of OPKO Health, Inc. and its subsidiaries (the “Company”), with respect to transactions in the Company’s securities an |
|
| March 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive |
|
| March 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive |
|
| March 11, 2025 |
Exhibit 2.1 EXECUTION VERSION ASSET PURCHASE AGREEMENT dated as of March 10, 2025 by and among BIOREFERENCE HEALTH, LLC, OPKO HEALTH, INC. and LABORATORY CORPORATION OF AMERICA HOLDINGS TABLE OF CONTENTS Page Article I SALE AND TRANSFER OF PURCHASED ASSETS 1 1.1 Purchased Assets 1 1.2 Excluded Assets 3 1.3 Assumption of Liabilities 4 1.4 Excluded Liabilities 4 1.5 Closing Purchase Price and Earnou |
|
| March 11, 2025 |
Exhibit 99.1 Labcorp Contacts: Investors: [email protected] Media: [email protected] OPKO Health Contacts: Yvonne Briggs, Alliance Advisors IR (investors) - 310-691-7100 [email protected] Bruce Voss, Alliance Advisors IR (investors) - 310-691-7100 [email protected] Labcorp Announces Acquisition of Select Assets of BioReference Health’s Innovative Oncology and Related Clinica |
|
| March 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2025 OPKO Health, Inc. |
|
| March 3, 2025 |
OPKO Health, Inc. Related Party Transaction Policy. Exhibit 19.1 OPKO HEALTH, INC. Related Party Transaction Policies and Procedures (Revised May 3, 2022) Policy OPKO Health, Inc. (the “Company”) recognizes that “Related Party Transactions” (as defined below) may raise questions as to whether those transactions are consistent with the best interests of the Company. It is the Company's policy to enter into or ratify Related Party Transactions only w |
|
| March 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024. |
|
| March 3, 2025 |
Exhibit 21.0 SUBSIDIARIES OF OPKO HEALTH, INC. NAME JURISDICTION OF INCORPORATION OPKO Pharmaceuticals, LLC Delaware OPKO Diagnostics, LLC Delaware ModeX Therapeutics, Inc. Delaware OPKO Chile, S.A. Chile Arama Natural Products Distribuidora, Ltda Chile Pharmacos Exakta S.A. de C.V. Mexico FineTech Pharmaceutical Ltd Israel OPKO Health Europe, S.L. Spain OPKO Biologics, Ltd Israel OPKO Renal, LLC |
|
| February 27, 2025 |
Exhibit 99.1 OPKO Health Reports Fourth Quarter 2024 Business Highlights and Financial Results Conference call begins at 4:30 p.m. Eastern time today MIAMI (February 27, 2025) – OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and 12 months ended December 31, 2024. Highlights from the fourth quarter of 2024 and recent weeks include the following: ● En |
|
| February 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2025 OPKO Health, Inc. |
|
| January 15, 2025 |
OPKO Health, Inc. Presentation Materials Exhibit 99.1 |
|
| January 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 15, 2025 OPKO Health, Inc. |
|
| November 20, 2024 |
WGS / GeneDx Holdings Corp. / OPKO HEALTH, INC. - SCHEDULE 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 9*) GeneDx Holdings, Corp. (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securities) 81663L200 (CUSIP Number) Steven D. Rubin Executive Vice President - Administration OPKO Health, Inc. 4400 Biscayne Boulevard Miami, Florida 33137 |
|
| November 15, 2024 |
OPK / OPKO Health, Inc. / FROST PHILLIP MD ET AL - SCHEDULE 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 25)* OPKO Health, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 68375N103 (CUSIP Number) Camielle Green Associate General Counsel, Secretary OPKO Health, Inc. 4400 Biscayne Boulevard Miami, Florida 33137 Telephone: (305) 57 |
|
| November 13, 2024 |
OPK / OPKO Health, Inc. / Rubric Capital Management LP - SC 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* OPKO Health, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 68375N103 (CUSIP Number) September 30, 2024 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which this Sc |
|
| November 8, 2024 |
WGS / GeneDx Holdings Corp. / OPKO HEALTH, INC. - SCHEDULE 13D/A Activist Investment SC 13D/A 1 opk20241107sc13da.htm SCHEDULE 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 8*) GeneDx Holdings, Corp. (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securities) 81663L200 (CUSIP Number) Steven D. Rubin Executive Vice President - Administration OPKO Health, I |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024. |
|
| November 7, 2024 |
Exhibit 99.1 OPKO Health Reports Third Quarter 2024 Business Highlights and Financial Results Conference call begins at 4:30 p.m. Eastern time today MIAMI (November 7, 2024) – OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and nine months ended September 30, 2024. Highlights from the third quarter of 2024 and recent weeks include the following: ● Co |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2024 OPKO Health, Inc. |
|
| September 18, 2024 |
WGS / GeneDx Holdings Corp. / OPKO HEALTH, INC. - SCHEDULE 13D/A Activist Investment SC 13D/A 1 opk20240917sc13da.htm SCHEDULE 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 7*) GeneDx Holdings, Corp. (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securities) 81663L200 (CUSIP Number) Steven D. Rubin Executive Vice President - Administration OPKO Health, I |
|
| September 16, 2024 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Labcorp Contacts: Christin O’Donnell (investors) – 336-436-5076 [email protected] Kimbrel Arculeo (media) – 336-436-8263 [email protected] OPKO Health Contacts: Yvonne Briggs, LHA Investor Relations (investors) - 310-691-7100 [email protected] Bruce Voss, LHA Investor Relations (investors) - 310-691-7100 [email protected] Labcorp Completes Acquisition of Select As |
|
| September 16, 2024 |
OPKO HEALTH, INC.AND SUBSIDIARIES SUMMARY OF UNAUDITED PRO FORMA CONSOLIDATED FINANCIAL STATEMENTS Exhibit 99.2 OPKO HEALTH, INC.AND SUBSIDIARIES SUMMARY OF UNAUDITED PRO FORMA CONSOLIDATED FINANCIAL STATEMENTS On March 27, 2024, OPKO Health Inc. (the “Company”), the Company’s indirect wholly owned subsidiary, BioReference Health, LLC (“BioReference”), and Laboratory Corporation of America Holdings, a Delaware corporation (“Labcorp”), entered into an Asset Purchase Agreement (the “Purchase Agre |
|
| September 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 16, 2024 OPKO Health, Inc. |
|
| August 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Amendment No. 1) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi |
|
| August 29, 2024 |
OPK / OPKO Health, Inc. / FROST PHILLIP MD ET AL - SCHEDULE 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 24)* OPKO Health, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 68375N103 (CUSIP Number) Camielle Green Associate General Counsel, Secretary OPKO Health, Inc. 4400 Biscayne Boulevard Miami, Florida 33137 Telephone: (305) 57 |
|
| August 23, 2024 |
WGS / GeneDx Holdings Corp. / OPKO HEALTH, INC. - SCHEDULE 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 6*) GeneDx Holdings, Corp. (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securities) 81663L200 (CUSIP Number) Steven D. Rubin Executive Vice President - Administration OPKO Health, Inc. 4400 Biscayne Boulevard Miami, Florida 33137 |
|
| August 12, 2024 |
WGS / GeneDx Holdings Corp. / OPKO HEALTH, INC. - SCHEDULE 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 5*) GeneDx Holdings, Corp. (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securities) 81663L200 (CUSIP Number) Steven D. Rubin Executive Vice President - Administration OPKO Health, Inc. 4400 Biscayne Boulevard Miami, Florida 33137 |
|
| August 7, 2024 |
Exhibit 10.2 NEITHER THIS DEBT INSTRUMENT NOR THE NOTES ISSUED IN CONNECTION HEREWITH HAVE BEEN REGISTERED UNDER THE SECURITIES ACT, OR ANY APPLICABLE STATE SECURITIES LAWS. SUCH SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT PURPOSES AND MAY NOT BE OFFERED FOR SALE, SOLD, DELIVERED AFTER SALE, TRANSFERRED, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FILED BY THE IS |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2024 OPKO Health, Inc. |
|
| August 7, 2024 |
Exhibit 99.1 OPKO Health Reports Second Quarter 2024 Business Highlights and Financial Results Conference call begins at 4:30 p.m. Eastern time today MIAMI (August 7, 2024) – OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and six months ended June 30, 2024. Highlights from the second quarter and recent weeks include the following: ● Enrollment under |
|
| August 7, 2024 |
Exhibit 10.1 CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. OMISSIONS ARE IDENTIFIED AS [***] NEITHER THIS DEBT INSTRUMENT NOR THE NOTES ISSUED IN CONNECTION HEREWITH HAVE BEEN REGISTERED UNDER THE SECURITIES ACT (AS DEFINED BELOW), OR ANY APPLICABLE STATE SECURITIES |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024. |
|
| July 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2024 OPKO Health, Inc. |
|
| July 26, 2024 |
WGS / GeneDx Holdings Corp. / OPKO HEALTH, INC. - SCHEDULE 13D/A Activist Investment SC 13D/A 1 opk20240725sc13da.htm SCHEDULE 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 4*) GeneDx Holdings, Corp. (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securities) 81663L200 (CUSIP Number) Steven D. Rubin Executive Vice President - Administration OPKO Health, I |
|
| July 17, 2024 |
Exhibit 99.1 OPKO Health and HealthCare Royalty Enter into $250 Million Note Purchase Agreement Secured by NGENLA’s Profit Share Payments MIAMI (July 17, 2024) – OPKO Health, Inc. (NASDAQ: OPK) announces it has entered into a $250 million non-dilutive note purchase agreement with HealthCare Royalty (HCRx) secured by OPKO’s profit share payments from Pfizer received pursuant to its license agreemen |
|
| July 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 17, 2024 OPKO Health, Inc. |
|
| July 5, 2024 |
WGS / GeneDx Holdings Corp. / OPKO HEALTH, INC. - SCHEDULE 13D/A Activist Investment SC 13D/A 1 opk20240613sc13da.htm SCHEDULE 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 3*) GeneDx Holdings, Corp. (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securities) 81663L200 (CUSIP Number) Steven D. Rubin Executive Vice President - Administration OPKO Health, I |
|
| May 7, 2024 |
Exhibit 99.1 OPKO Health Reports First Quarter 2024 Business Highlights and Financial Results Conference call begins at 4:30 p.m. Eastern time today MIAMI (May 7, 2024) – OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended March 31, 2024. First quarter business highlights include the following: ● Entered into an agreement with Labcorp to sel |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2024 OPKO Health, Inc. |
|
| May 7, 2024 |
Exhibit 3.1 THIS COMPOSITE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF OPKO HEALTH, INC. (THE “CORPORATION”) REFLECTS THE PROVISIONS OF THE CORPORATION’S CERTIFICATE OF INCORPORATION AND ALL AMENDMENTS THERETO FILED WITH THE DELAWARE SECRETARY OF STATE THEREAFTER ON OR PRIOR TO APRIL 1, 2024, BUT IS NOT AN AMENDMENT AND/OR RESTATEMENT THEREOF. COMPOSITE AMENDED AND RESTATED CERTIFICATE OF |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024. |
|
| March 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2024 OPKO Health, Inc. |
|
| March 28, 2024 |
Exhibit 2.1 ASSET PURCHASE AGREEMENT dated as of March 27, 2024 by and among BIOREFERENCE HEALTH, LLC, OPKO HEALTH, INC. and LABORATORY CORPORATION OF AMERICA HOLDINGS TABLE OF CONTENTS Page ARTICLE I SALE AND TRANSFER OF PURCHASED ASSETS 1.1 Purchased Assets 1 1.2 Excluded Assets 3 1.3 Assumption of Liabilities 4 1.4 Excluded Liabilities 4 1.5 Purchase Price 5 1.6 Closing 6 1.7 Closing Deliverabl |
|
| March 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2024 OPKO Health, Inc. |
|
| March 28, 2024 |
Exhibit 2.1 ASSET PURCHASE AGREEMENT dated as of March 27, 2024 by and among BIOREFERENCE HEALTH, LLC, OPKO HEALTH, INC. and LABORATORY CORPORATION OF AMERICA HOLDINGS TABLE OF CONTENTS Page ARTICLE I SALE AND TRANSFER OF PURCHASED ASSETS 1.1 Purchased Assets 1 1.2 Excluded Assets 3 1.3 Assumption of Liabilities 4 1.4 Excluded Liabilities 4 1.5 Purchase Price 5 1.6 Closing 6 1.7 Closing Deliverabl |
|
| March 28, 2024 |
Exhibit 99.1 |
|
| March 28, 2024 |
Investor Presentation, dated March 27, 2024 Exhibit 99.1 |
|
| March 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2024 OPKO Health, Inc. |
|
| March 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023. |
|
| March 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: December 31, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Pe |
|
| March 1, 2024 |
Exhibit 21 SUBSIDIARIES OF OPKO HEALTH, INC. NAME JURISDICTION OF INCORPORATION OPKO Instrumentation, LLC Delaware OPKO Pharmaceuticals, LLC Delaware OPKO Diagnostics, LLC Delaware ModeX Therapeutics, Inc. Delaware OPKO Chile, S.A. Chile Arama Natural Products Distribuidora, Ltda Chile Pharmacos Exakta S.A. de C.V. Mexico FineTech Pharmaceutical Ltd Israel OPKO Health Europe, S.L. Spain OPKO Biolo |
|
| March 1, 2024 |
OPKO Health, Inc. Executive Officer Clawback Policy Approved by the Compensation Committee on November 1, 2023 (the “Adoption Date”) I. Purpose This Executive Officer Clawback Policy describes the circumstances under which Covered Persons of OPKO Health, Inc., a Delaware corporation, and any of its direct or indirect subsidiaries (collectively, the “Company”) will be required to repay or return Er |
|
| February 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive |
|
| February 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2024 OPKO Health, Inc. |
|
| February 27, 2024 |
Exhibit 99.1 OPKO Health Reports Fourth Quarter 2023 Business Highlights and Financial Results Conference call begins at 4:30 p.m. Eastern time today MIAMI (February 27, 2024) – OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and 12 months ended December 31, 2023. Business highlights from the fourth quarter and subsequent weeks included the following |
|
| February 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive |
|
| February 13, 2024 |
OPK / OPKO Health, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01620-opkohealthinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 5)* Name of issuer: OPKO Health Inc Title of Class of Securities: Common Stock CUSIP Number: 68375N103 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the |
|
| February 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 9, 2024 OPKO Health, Inc. |
|
| January 24, 2024 |
OPK / OPKO Health, Inc. / FROST PHILLIP MD ET AL - SCHEDULE 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 23)* OPKO Health, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 68375N103 (CUSIP Number) Camielle Green Associate General Counsel, Secretary OPKO Health, Inc. 4400 Biscayne Boulevard Miami, Florida 33137 Telephone: (305) 57 |
|
| January 24, 2024 |
OPK / OPKO Health, Inc. / HSIAO JANE PH D - SCHEDULE 13D/A Activist Investment SC 13D/A 1 hjhp20240124sc13da.htm SCHEDULE 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 10*) OPKO Health, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 68375N103 (CUSIP Number) Camielle Green Associate General Counsel, Secretary OPKO Health, Inc. 4400 Biscayne B |
|
| January 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 22, 2024 OPKO Health, Inc. |
|
| January 22, 2024 |
OPK / OPKO Health, Inc. / FROST PHILLIP MD ET AL - SCHEDULE 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 22)* OPKO Health, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 68375N103 (CUSIP Number) Camielle Green Associate General Counsel, Secretary OPKO Health, Inc. 4400 Biscayne Boulevard Miami, Florida 33137 Telephone: (305) 57 |
|
| January 9, 2024 |
Exhibit 10.1 OPKO Health, Inc. 3.75% Convertible Senior Notes due 2029 Purchase Agreement January 4, 2024 J.P. Morgan Securities LLC As Representative of the several Initial Purchasers listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 Ladies and Gentlemen: OPKO Health, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to t |
|
| January 9, 2024 |
Exhibit 4.1 OPKO HEALTH, INC. (Company) U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION (Trustee) 3.75% Convertible Senior Notes due 2029 INDENTURE Dated as of January 9, 2024 TABLE OF CONTENTS PAGE ARTICLE 1. DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 1 Section 1.01 Definitions; Terms Generally 1 Section 1.02 References to Interest 14 Section 1.03 Acts of Holders 15 ARTICLE 2. THE NOTE |
|
| January 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 4, 2024 OPKO Health, Inc. |
|
| January 9, 2024 |
Exhibit 10.2 CONVERTIBLE NOTE PURCHASE AGREEMENT This CONVERTIBLE NOTE PURCHASE AGREEMENT (this “Agreement”) is made as of January 4, 2024 by and among OPKO Health, Inc., a Delaware corporation (the “Company”), and each of the purchasers identified on the signature pages hereto (each, a “Purchaser” and, together, the “Purchasers”). RECITALS WHEREAS, the Company has entered into a note purchase agr |
|
| January 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 4, 2024 OPKO Health, Inc. |
|
| January 5, 2024 |
Exhibit 99.1 OPKO Health Announces Pricing of Private Offering of $200 Million Convertible Senior Notes Due 2029 Proceeds to be used for privately negotiated repurchases of common stock and outstanding 4.50% Convertible Senior Notes due 2025 MIAMI (January 4, 2024) – OPKO Health, Inc. (NASDAQ: OPK) (the “Company”) today announced the pricing of its private offering of $200.0 million aggregate prin |
|
| January 4, 2024 |
Regulation FD Disclosure, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2024 OPKO Health, Inc. |
|
| January 4, 2024 |
Exhibit 99.2 OPKO Health Announces Private Offering of Convertible Senior Notes Due 2029 Proceeds to be used for privately negotiated repurchases of common stock and outstanding 4.50% Convertible Senior Notes due 2025 MIAMI, January 3, 2024 – OPKO Health, Inc. (Nasdaq: OPK) (the “Company”) today announced that it is commencing a private offering of $200.0 million aggregate principal amount of its |
|
| January 4, 2024 |
Investor Presentation, dated January 3, 2024. Exhibit 99.1 |
|
| November 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023. |
|
| November 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2023 OPKO Health, Inc. |
|
| November 6, 2023 |
Exhibit 99.1 OPKO Health Reports Third Quarter 2023 Business Highlights and Financial Results Conference call begins at 4:30 p.m. Eastern time today MIAMI (November 6, 2023) – OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and nine months ended September 30, 2023. Business highlights from the third quarter and subsequent weeks included the following |
|
| October 31, 2023 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A (Amendment No. |
|
| September 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 28, 2023 OPKO Health, Inc. |
|
| September 28, 2023 |
ModeX Therapeutics Secures BARDA Contract to Develop Novel Multispecific Antibodies Against Viral Infectious Disease Threats Provides Initial $59 Million and up to $168 Million Contingent on Milestones NATICK, Mass. |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2023 OPKO Health, Inc. |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023. |
|
| August 3, 2023 |
OPKO Health Reports Second Quarter 2023 Business Highlights and Financial Results Conference call begins at 4:30 p. |
|
| August 3, 2023 |
Exhibit 10.1 EXECUTION VERSION WAIVER UNDER AND AMENDMENT NO. 2 TO AMENDED AND RESTATED CREDIT AGREEMENT WAIVER UNDER AND AMENDMENT NO. 2 TO AMENDED AND RESTATED CREDIT AGREEMENT (this “Amendment”), dated as of June 29, 2023, is entered into among BIOREFERENCE HEALTH, LLC, a Delaware limited liability company and successor to BIO-REFERENCE LABORATORIES, INC., a New Jersey corporation (“Company”), |
|
| June 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2023 OPKO Health, Inc. |
|
| June 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2023 OPKO Health, Inc. |
|
| May 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2023 OPKO Health, Inc. |
|
| May 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive |
|
| May 15, 2023 |
As filed with the Securities and Exchange Commission on May 15, 2023 As filed with the Securities and Exchange Commission on May 15, 2023 Registration No. |
|
| May 15, 2023 |
Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) OPKO Health, Inc. (Exact name of registrant as specified in its charter) Table 1 - Newly Registered Securities Security Type Security Class Title Fee Calculation Rule(2) Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par val |
|
| May 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023. |
|
| May 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2023 OPKO Health, Inc. |
|
| May 3, 2023 |
CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. |
|
| May 3, 2023 |
Exhibit 99.1 OPKO Health Reports First Quarter 2023 Business Highlights and Financial Results Conference call begins at 4:30 p.m. Eastern time today MIAMI (May 3, 2023) – OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended March 31, 2023. First quarter business highlights include the following: ● OPKO Health’s ModeX Therapeutics, Inc. (ModeX |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive |
|
| April 20, 2023 |
SMFR / Sema4 Holdings Corp - Class A / OPKO HEALTH, INC. - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 2) GeneDx Holdings, Corp. (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securities) 81663L101 (CUSIP Number) Steven D. Rubin Executive Vice President - Administration OPKO Health, Inc. 4400 Biscayne Boulevard Miami, Florida 33137 |
|
| March 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2023 OPKO Health, Inc. |
|
| March 8, 2023 |
OPKO Health’s ModeX Therapeutics Enters into Exclusive Worldwide License and Collaboration Agreement with Merck to Develop Epstein-Barr Virus Vaccine Candidate •MDX-2201 leverages ModeX’s innovative biologics platform to target multiple Epstein-Barr virus (EBV) proteins •EBV is the leading cause of infectious mononucleosis and is also associated with some specific types of cancer MIAMI (March 8, 2023) – OPKO Health, Inc. |
|
| February 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022. |
|
| February 27, 2023 |
Exhibit 21 SUBSIDIARIES OF OPKO HEALTH, INC. NAME JURISDICTION OF INCORPORATION OPKO Instrumentation, LLC Delaware OPKO Pharmaceuticals, LLC Delaware OPKO Diagnostics, LLC Delaware ModeX Therapeutics, Inc. Delaware OPKO Chile, S.A. Chile Arama Natural Products Distribuidora, Ltda Chile Pharmacos Exakta S.A. de C.V. Mexico FineTech Pharmaceutical Ltd Israel OPKO Health Europe, S.L. Spain OPKO Biolo |
|
| February 27, 2023 |
THIS AMENDED AND RESTATED 5% CONVERTIBLE PROMISSORY NOTE AND THE SECURITIES ISSUABLE UPON CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY STATE SECURITIES LAWS, IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT, AND, ACCORDINGLY, MAY NOT BE OFFERED, SOLD, MORTGAGED, PLEDGED, HYPOTHECATED, OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND OTHERWISE IN COMPLIANCE WITH APPLICABLE STATE SECURITIES LAWS. |
|
| February 23, 2023 |
OPKO Health Reports Fourth Quarter 2022 Business Highlights and Financial Results Conference call begins at 4:30 p. |
|
| February 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2023 OPKO Health, Inc. |
|
| February 21, 2023 |
OPK / Opko Health Inc / FROST PHILLIP MD ET AL - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 21)* OPKO Health, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 68375N103 (CUSIP Number) Camielle Green Associate General Counsel, Secretary OPKO Health, Inc. 4400 Biscayne Boulevard Miami, Florida 33137 Telephone: (305) 57 |
|
| February 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 10, 2023 OPKO Health, Inc. |
|
| February 9, 2023 |
OPK / Opko Health Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01588-opkohealthinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)* Name of issuer: OPKO Health Inc. Title of Class of Securities: Common Stock CUSIP Number: 68375N103 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the |
|
| February 3, 2023 |
SMFR / Sema4 Holdings Corp. Class A / OPKO HEALTH, INC. - SC 13D/A Activist Investment SC 13D/A 1 sc13dagenedx12623.htm SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1) GeneDx Holdings, Corp. (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securities) 81663L101 (CUSIP Number) Steven D. Rubin Executive Vice President - Administration OPKO Health, Inc. 440 |
|
| January 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2023 OPKO Health, Inc. |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2022 OPKO Health, Inc. |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022. |
|
| November 8, 2022 |
OPKO Health Reports Third Quarter 2022 Business Highlights and Financial Results Conference call begins at 4:30 p. |
|
| August 19, 2022 |
OPK / Opko Health Inc. / FROST PHILLIP MD ET AL - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 20)* OPKO Health, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 68375N103 (CUSIP Number) Camielle Green Associate General Counsel, Secretary OPKO Health, Inc. 4400 Biscayne Boulevard Miami, Florida 33137 Telephone: (305) 57 |
|
| August 19, 2022 |
OPK / Opko Health Inc. / HSIAO JANE PH D - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 9)* OPKO Health, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 68375N103 (CUSIP Number) Camielle Green Associate General Counsel, Secretary OPKO Health, Inc. 4400 Biscayne Boulevard Miami, Florida 33137 Telephone: (305) 575 |
|
| August 16, 2022 |
SEVERANCE AGREEMENT AND GENERAL RELEASE This SEVERANCE AGREEMENT AND GENERAL RELEASE (the ?Agreement?) is between Jon R. |
|
| August 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 16, 2022 OPKO Health, Inc. |
|
| August 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2022 OPKO Health, Inc. |
|
| August 5, 2022 |
OPKO Health Reports 2022 Second Quarter Business Highlights and Financial Results Conference call begins at 4:30 p. |
|
| August 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022. |
|
| July 15, 2022 |
CORPORATE INTEGRITY AGREEMENT BETWEEN THE OFFICE OF INSPECTOR GENERAL OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES AND OPKO HEALTH, INC. |
|
| July 15, 2022 |
SETTLEMENT AGREEMENT This Settlement Agreement (?Agreement?) is entered into among the United States of America, acting through the United States Department of Justice and on behalf of the Office of Inspector General (?OIG-HHS?) of the Department of Health and Human Services (?HHS?), and the Defense Health Agency (?DHA?), acting on behalf of the TRICARE Program (collectively, the ?United States?), |
|
| July 15, 2022 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 14, 2022 OPKO Health, Inc. |
|
| June 29, 2022 |
OPK / Opko Health Inc. / Nabel Gary J. - SC 13D Activist Investment SC 13D 1 d376218dsc13d.htm SC 13D SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Amendment No. ( )* OPKO HEALTH, INC. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 68375N103 (CUSIP Number) Stuart Cable, Esq. Ed Amer, Esq. Folake Ayoola, Esq. Goodwin Procter LLP 100 Northern Avenue Boston, MA |
|
| June 29, 2022 |
OPK / Opko Health Inc. / Zerhouni Elias A. - SC 13D Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Amendment No. ( )* OPKO HEALTH, INC. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 68375N103 (CUSIP Number) Stuart Cable, Esq. Ed Amer, Esq. Folake Ayoola, Esq. Goodwin Procter LLP 100 Northern Avenue Boston, MA 02210 Telephone: (617) 570-1000 ( |
|
| June 29, 2022 |
CUSIP No. 68375N103 13D EXHIBIT 1 JOINT FILING AGREEMENT Pursuant to Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, each of the undersigned acknowledges and agrees that the foregoing statement on this Schedule 13D is filed on behalf of the undersigned and that all subsequent amendments to this statement on Schedule 13D shall be filed on behalf of the undersigne |
|
| June 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive |
|
| June 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive |
|
| May 13, 2022 |
EXECUTION VERSION AGREEMENT AND PLAN OF MERGER OPKO HEALTH, INC., ORCA ACQUISITION SUB, INC., MODEX THERAPEUTICS, INC., and SELLERS? REPRESENTATIVE DATED AS OF MAY 9, 2022 TABLE OF CONTENTS 1. The Merger 1 1.1 The Merger 1 1.2 Effective Time; Effect of the Merger 2 1.3 Certificate of Incorporation and Bylaws of the Surviving Corporation 2 1.4 Directors and Officers of the Surviving Corporation 2 1 |
|
| May 13, 2022 |
Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2022 OPKO Health, Inc. |
|
| May 13, 2022 |
LOCK-UP AND VOTING AGREEMENT This LOCK-UP AND VOTING AGREEMENT (this ?Agreement?) is made as of May 9, 2022 by and among OPKO Health, Inc. |
|
| May 13, 2022 |
Offer Letter, dated May 9. 2022, by and between the Company and Dr. Nabel. May 9, 2022 Gary Nabel, M.D., Ph.D. 815 Palm Trail Unit Zilla Delray Beach, FL 33483 Sent via email: [email protected] Dear Gary, On behalf of OPKO Health, Inc. (the "Company"), it is my pleasure to extend to you an offer of employment with the Company upon the terms and conditions set forth in this letter agreement. Your expected employment start date will be May 9, 2022. Our offer includes |
|
| May 13, 2022 |
Offer Letter, dated May 9, 2022, by and between the Company and Dr. Zerhouni. May 9, 2022 Elias Zerhouni, M.D. 2200 N. Ocean Blvd. Unit S2004 Fort Lauderdale, FL 33305 Sent via email: [email protected] Dear Elias, On behalf of OPKO Health, Inc. (the "Company"), it is my pleasure to extend to you an offer of employment with the Company upon the terms and conditions set forth in this letter agreement. Your expected employment start date will be May 10, 2022. Our offer |
|
| May 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022. |
|
| May 9, 2022 |
OPKO Health Reports 2022 First Quarter Business Highlights and Financial Results Conference call begins at 4:30 p. |
|
| May 9, 2022 |
SMFR / Sema4 Holdings Corp. Class A / OPKO HEALTH, INC. - SC 13D Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Sema4 Holdings, Corp. (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securities) 81663L101 (CUSIP Number) Steven D. Rubin Executive Vice President - Administration OPKO Health, Inc. 4400 Biscayne Boulevard Miami, Florida 33137 Telephone: (305) 575- |
|
| May 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2022 OPKO Health, Inc. |
|
| May 4, 2022 |
Exhibit 10-1 EXECUTION VERSION WAIVER UNDER AND AMENDMENT NO. 1 TO AMENDED AND RESTATED CREDIT AGREEMENT WAIVER UNDER AND AMENDMENT NO. 1 TO AMENDED AND RESTATED CREDIT AGREEMENT (this ?Amendment?), dated as of April 29, 2022, is entered into among BIOREFERENCE HEALTH, LLC, a Delaware limited liability company and successor to BIO-REFERENCE LABORATORIES, INC., a New Jersey corporation (?Company?), |
|
| May 4, 2022 |
Entry into a Material Definitive Agreement, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2022 OPKO Health, Inc. |
|
| May 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K/A (Amendment No. 1) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K/A (Amendment No. |
|
| April 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 21, 2022 OPKO Health, Inc. |
|
| April 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2022 OPKO Health, Inc. |
|
| March 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021. |
|
| March 1, 2022 |
Exhibit 21 SUBSIDIARIES OF OPKO HEALTH, INC. NAME JURISDICTION OF INCORPORATION OPKO Instrumentation, LLC Delaware OPKO Pharmaceuticals, LLC Delaware OPKO Diagnostics, LLC Delaware OPKO Chile, S.A. Chile Arama Natural Products Distribuidora, Ltda Chile Pharmacos Exakta S.A. de C.V. Mexico FineTech Pharmaceutical Ltd Israel OPKO Health Europe, S.L. Spain OPKO Biologics, Ltd Israel OPKO Ireland Glob |
|
| February 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2022 OPKO Health, Inc. |
|
| February 24, 2022 |
OPKO Health Reports 2021 Fourth Quarter Business Highlights and Financial Results Conference call begins at 4:30 p. |
|
| February 10, 2022 |
OPK / Opko Health Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: OPKO Health Inc. Title of Class of Securities: Common Stock CUSIP Number: 68375N103 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ??Ru |
|
| January 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 21, 2022 OPKO Health, Inc. |
|
| January 18, 2022 |
EXECUTION VERSION AGREEMENT AND PLAN OF MERGER AND REORGANIZATION by and among SEMA4 HOLDINGS CORP. |
|
| January 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 14, 2022 OPKO Health, Inc. |
|
| January 18, 2022 |
SHAREHOLDER AGREEMENT January 14, 2022 Sema4 Holdings Corp. 333 Ludlow Street, North Tower, 8th floor Stamford, CT 06902 Ladies and Gentlemen: This letter agreement (this ?Agreement?) relates to that certain Agreement and Plan of Merger, dated as of January 14, 2022 (as amended, restated, supplemented or modified from time to time, the ?Merger Agreement?), by and among Sema4 Holdings Corp., a Dela |
|
| October 28, 2021 |
OPKO Health Reports 2021 Third Quarter Business Highlights and Financial Results Conference call begins at 4:30 p. |
|
| October 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021. |
|
| October 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2021 OPKO Health, Inc. |
|
| September 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 30, 2021 OPKO Health, Inc. |
|
| September 3, 2021 |
EXECUTION VERSION AMENDED AND RESTATED CREDIT AGREEMENT dated as of August 30, 2021, among BIO-REFERENCE LABORATORIES, INC. |
|
| July 29, 2021 |
EXECUTION VERSION ASSET PURCHASE AGREEMENT Among EirGen Pharma Limited, Horizon Therapeutics Ireland DAC And OPKO Health, Inc. |
|
| July 29, 2021 |
CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. |
|
| July 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2021 OPKO Health, Inc. |
|
| July 29, 2021 |
License Agreement by and among EirGen Pharma Limited and Nicoya Macua Limited, dated June 18, 2021. CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. |
|
| July 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021. |
|
| July 29, 2021 |
OPKO Health Reports 2021 Second Quarter Business Highlights and Financial Results Conference call begins at 4:30 p. |
|
| July 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 6, 2021 OPKO Health, Inc. |
|
| June 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2021 OPKO Health, Inc. |
|
| June 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2021 OPKO Health, Inc. |
|
| June 21, 2021 |
OPKO Health to Develop and Commercialize RAYALDEE® in Greater China with Nicoya Therapeutics OPKO Health to Develop and Commercialize RAYALDEE? in Greater China with Nicoya Therapeutics MIAMI (June 21, 2021) ? OPKO Health, Inc. |
|
| June 21, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2021 OPKO Health, Inc. |
|
| May 21, 2021 |
Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2021 OPKO Health, Inc. |
|
| May 7, 2021 |
EXCHANGE AGREEMENT This Exchange Agreement (this ?Agreement?) is made and entered into as of May 6, 2021, by and between OPKO Health, Inc. |
|
| May 7, 2021 |
Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2021 OPKO Health, Inc. |
|
| April 30, 2021 |
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Statement x Definitive Additional Materials ? Soliciting Material under 240. |
|
| April 30, 2021 |
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy Statement ? Definitive Additional Materials ? Soliciting Material under 240. |
|
| April 28, 2021 |
OPKO Health Reports 2021 First Quarter Business Highlights and Financial Results Conference call begins at 4:30 p. |
|
| April 28, 2021 |
OPKO Health to Report First Quarter 2021 Financial Results on April 28, 2021 EX-99.2 3 a992pressrelease42221.htm EX-99.2 OPKO Health to Report First Quarter 2021 Financial Results on April 28, 2021 MIAMI (April 22, 2021) – OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended March 31, 2021, as well as discuss financial guidance, after the close of the U.S. financial markets on Wednesday, April 28, 2021. OPKO’s senior ma |
|
| April 28, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021. |
|
| April 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2021 OPKO Health, Inc. |
|
| March 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2021 OPKO Health, Inc. |
|
| March 17, 2021 |
EXECUTION VERSION AMENDMENT NO. 12 TO CREDIT AGREEMENT AMENDMENT NO. 12 TO CREDIT AGREEMENT (this ?Amendment?), dated as of March 12, 2021, is entered into among BIO-REFERENCE LABORATORIES, INC., a New Jersey corporation (?Company?), the Subsidiary Borrowers party hereto (?Subsidiary Borrowers,? and together with Company, each a ?Borrower? and, collectively, the ?Borrowers?), the other Loan Partie |
|
| March 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2021 OPKO Health, Inc. |
|
| February 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 19, 2021 OPKO Health, Inc. |
|
| February 18, 2021 |
OPKO Health Reports 2020 Fourth Quarter Business Highlights and Financial Results Conference call begins at 4:30 p. |
|
| February 18, 2021 |
Exhibit 4.6 DESCRIPTION OF COMMON STOCK As of the end of the period covered by the most recent Annual Report on Form 10-K of OPKO Health, Inc.(the ?registrant?), the common stock, par value $0.01 per share, of the registrant (the ?common stock?) was registered under Section 12 of the Securities Exchange Act of 1934, as amended. Unless the context otherwise requires, all references herein to ?we?, |
|
| February 18, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 18, 2021 OPKO Health, Inc. |
|
| February 18, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020. |
|
| February 18, 2021 |
Exhibit 21 SUBSIDIARIES OF OPKO HEALTH, INC. NAME JURISDICTION OF INCORPORATION OPKO Instrumentation, LLC Delaware OPKO Pharmaceuticals, LLC Delaware OPKO Diagnostics, LLC Delaware OPKO Chile, S.A. Chile Arama Natural Products Distribuidora, Ltda Chile Pharmacos Exakta S.A. de C.V. Mexico FineTech Pharmaceutical Ltd Israel OPKO Health Europe, S.L. Spain OPKO Biologics, Ltd Israel OPKO Ireland Glob |
|
| February 18, 2021 |
AMENDED AND RESTATED BYLAWS OF OPKO HEALTH, INC. (A DELAWARE CORPORATION) Effective: February 12, 2021 Article I. OFFICES Section 1.1 Registered Office. The registered office of OPKO Health, Inc. (the ?Corporation?) shall be in the City of Wilmington, County of New Castle, State of Delaware. Notwithstanding the foregoing, the registered office may be changed at any time upon a resolution adopted b |
|
| February 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: OPKO Health Inc. Title of Class of Securities: Common Stock CUSIP Number: 68375N103 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Ru |
|
| February 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 1, 2021 OPKO Health, Inc. |
|
| February 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 1, 2021 OPKO Health, Inc. |
|
| January 13, 2021 |
OPKO Health’s BioReference Laboratories Introduces Scarlet Health™, In-Home Diagnostic Service to Expand Digital Health Access Scarlet brings diagnostic service to patients’ homes, offices and other preferred locations, delivering an on-demand, safe and convenient diagnostic experience for patients and healthcare providers ELMWOOD PARK, N. |
|
| January 13, 2021 |
Regulation FD Disclosure - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2021 OPKO Health, Inc. |
|
| January 13, 2021 |
EX-99.1 2 ex9911-13x21.htm EX-99.1 January 2021 NASDAQ: OPK January 2021 | 2 This presentation contains “forward-looking statements,” as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “intends,” “estimates,” “potential,” a |
|
| December 21, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 18, 2020 OPKO Health, Inc. |
|
| November 19, 2020 |
COCP / Cocrystal Pharma, Inc. / OPKO HEALTH, INC. - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Cocrystal Pharma, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 19188J300 (CUSIP Number) Camielle Green Associate General Counsel, Secretary OPKO Health, Inc. 4400 Biscayne Boulevard Miami, Florida 33137 Telephone: (30 |
|
| October 29, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2020 OPKO Health, Inc. |
|
| October 29, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020. |
|
| October 29, 2020 |
OPKO Health Reports 2020 Third Quarter Business Highlights and Financial Results Conference call begins at 4:30 p. |
|
| September 15, 2020 |
Regulation FD Disclosure - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 15, 2020 OPKO Health, Inc. |
|
| September 15, 2020 |
opkohealthmanagementpres September 2020 NASDAQ: OPK Forward Looking Statements This presentation contains “forward-looking statements,” as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “intends,” “estimates,” “potential,” |
|
| July 31, 2020 |
EX-10.2 3 a102pfizerlicagmtamend.htm EX-10.2 CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. OMISSIONS ARE IDENTIFIED AS [***] CONFIDENTIAL EXECUTION VERSION AMENDED AND RESTATED DEVELOPMENT AND COMMERCIALIZATION LICENSE AGREEMENT This Amended and Restated Development |
|
| July 31, 2020 |
EX-10.1 2 a101viforlicagmtamend.htm EX-10.1 CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. OMISSIONS ARE IDENTIFIED AS [***] AMENDMENT TO DEVELOPMENT AND LICENSE AGREEMENT AMENDMENT AGREEMENT to Development and License Agreement effective as of 8 May 2016 (“the Agreem |
|
| July 31, 2020 |
OPKO Health Reports 2020 Second Quarter Business Highlights and Financial Results Conference call begins at 4:45 p. |
|
| July 31, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020. |
|
| July 31, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2020 OPKO Health, Inc. |
|
| July 31, 2020 |
OPKO Health to Report Second Quarter 2020 Financial Results on July 30, 2020 OPKO Health to Report Second Quarter 2020 Financial Results on July 30, 2020 MIAMI (July 27, 2020) – OPKO Health, Inc. |
|
| July 23, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 22, 2020 OPKO Health, Inc. |
|
| July 21, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 20, 2020 OPKO Health, Inc. |
|
| June 26, 2020 |
OPKO Health, Inc. (NASDAQ:OPK) 2020 Annual Meeting of Stockholders June 25, 2020 10:00 AM ET OPKO Health, Inc. (NASDAQ:OPK) 2020 Annual Meeting of Stockholders June 25, 2020 10:00 AM ET Company Participants Phillip Frost - Chairman and CEO Dr. Jane Hsiao - Vice Chairman and CTO Steve Rubin - Director & EVP Adam Logal - SVP & CFO Dr. Charles Bishop - CEO, Renal Division Dr. Tony Cruz - CEO, Transition Therapeutic Subsidiary Dr. Jon Cohen - Executive Chairman of BioReference Laboratories Ru |
|
| June 26, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2020 OPKO Health, Inc. |
|
| May 15, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2020 OPKO Health, Inc. |
|
| May 6, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020. |
|
| May 6, 2020 |
OPKO Health Reports 2020 First Quarter Business Highlights and Financial Results Conference call begins at 4:30 p. |
|
| May 6, 2020 |
OPKO Health to Report First Quarter 2020 Financial Results on May 6, 2020 OPKO Health to Report First Quarter 2020 Financial Results on May 6, 2020 MIAMI (April 30, 2020) – OPKO Health, Inc. |
|
| May 6, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2020 OPKO Health, Inc. |
|
| April 29, 2020 |
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy Statement ¨ Definitive Additional Materials ¨ Soliciting Material under 240. |
|
| April 29, 2020 |
DEFA14A 1 a2020proxydefa14a.htm DEFA14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy Statement x Definitive Ad |
|
| March 20, 2020 |
OPK / Opko Health, Inc. / HSIAO JANE PH D - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 8)* OPKO Health, Inc. (Name of Issuer) Common Shares, par value $0.01 per share (Title of Class of Securities) 68375N103 (CUSIP Number) Kate Inman General Counsel, Secretary OPKO Health, Inc. 4400 Biscayne Boulevard Miami, Florida 33137 Telephone: (305) 575-4100 (Name, |
|
| March 10, 2020 |
COCP / Cocrystal Pharma, Inc. / Opko Health, Inc. - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Cocrystal Pharma, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 19188J300 (CUSIP Number) Kate Inman General Counsel, Secretary OPKO Health, Inc. 4400 Biscayne Boulevard Miami, Florida 33137 Telephone: (305) 575-4100 Ph |
|
| March 2, 2020 |
EXECUTION VERSION AMENDMENT NO. 11 TO CREDIT AGREEMENT AMENDMENT NO. 11 TO CREDIT AGREEMENT (this “Amendment”), dated as of February 24, 2020, is entered into among BIO-REFERENCE LABORATORIES, INC., a New Jersey corporation (“Company”), the Subsidiary Borrowers party hereto (“Subsidiary Borrowers,” and together with Company, each a “Borrower” and, collectively, the “Borrowers”), the other Loan Par |
|
| March 2, 2020 |
Exhibit 21 SUBSIDIARIES OF OPKO HEALTH, INC. NAME JURISDICTION OF INCORPORATION OPKO Instrumentation, LLC Delaware OPKO Pharmaceuticals, LLC Delaware OPKO Diagnostics, LLC Delaware OPKO Chile, S.A. Chile Arama Natural Products Distribuidora, Ltda Chile Pharmacos Exakta S.A. de C.V. Mexico FineTech Pharmaceutical Ltd Israel Farmadiet Group Holdings, S.C. Spain OPKO Biologics, Ltd Israel OPKO Irelan |
|
| March 2, 2020 |
EXECUTION VERSION AMENDMENT NO. 10 TO CREDIT AGREEMENT AMENDMENT NO. 10 TO CREDIT AGREEMENT (this “Amendment”), dated as of November 4, 2019, is entered into among BIO-REFERENCE LABORATORIES, INC., a New Jersey corporation (“Company”), the Subsidiary Borrowers party hereto (“Subsidiary Borrowers,” and together with Company, each a “Borrower” and, collectively, the “Borrowers”), the other Loan Part |
|
| March 2, 2020 |
Exhibit 4.6 DESCRIPTION OF COMMON STOCK As of the end of the period covered by the most recent Annual Report on Form 10-K of OPKO Health, Inc.(the “registrant”), the common stock, par value $0.01 per share, of the registrant (the “common stock”) was registered under Section 12 of the Securities Exchange Act of 1934, as amended. Unless the context otherwise requires, all references herein to “we”, |
|
| March 2, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019. |
|
| March 2, 2020 |
OPKO HEALTH, INC. CREDIT AGREEMENT February 25, 2020 OPKO HEALTH, INC. CREDIT AGREEMENT This Credit Agreement (this "Agreement") is made as of the 25th day of February, 2020 by and among OPKO Health, Inc., a Delaware corporation (the "Company") and Frost Gamma Investments Trust, a Florida trust (the "Lender"). RECITAL The Company desires to borrow from the Lender, and the Lender desires to loan to |
|
| February 26, 2020 |
OPKO Health Reports 2019 Fourth Quarter Business Highlights and Financial Results Conference call begins at 4:30 p. |
|
| February 26, 2020 |
OPKO Health to Report Fourth Quarter 2019 Financial Results on February 26, 2020 OPKO Health to Report Fourth Quarter 2019 Financial Results on February 26, 2020 MIAMI (February 20, 2020) – OPKO Health, Inc. |
|
| February 26, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2020 OPKO Health, Inc. |
|
| February 12, 2020 |
OPK / Opko Health, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: OPKO Health Inc Title of Class of Securities: Common Stock CUSIP Number: 68375N103 Date of Event Which Requires Filing of this Statement: December 31, 2019 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rul |
|
| January 8, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2020 OPKO Health, Inc. |
|
| November 22, 2019 |
COCP / Cocrystal Pharma, Inc. / Opko Health, Inc. - SC 13D/A Activist Investment SC 13D/A 1 cocrystalsc13-da11x8x19.htm SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Cocrystal Pharma, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 19188J300 (CUSIP Number) Kate Inman General Counsel, Secretary OPKO Health, Inc. 4400 Biscayne Boulevard M |
|
| November 5, 2019 |
OPKO Health Reports 2019 Third Quarter Business Highlights and Financial Results Conference call begins at 4:30 p. |
|
| November 5, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2019 OPKO Health, Inc. |
|
| November 5, 2019 |
OPKO Health to Report Third Quarter 2019 Financial Results on November 5, 2019 OPKO Health to Report Third Quarter 2019 Financial Results on November 5, 2019 MIAMI (November 1, 2019) – OPKO Health, Inc. |
|
| November 5, 2019 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019. |
|
| November 5, 2019 |
EXECUTION VERSION AMENDMENT NO. 9 TO CREDIT AGREEMENT AMENDMENT NO. 9 TO CREDIT AGREEMENT (this “Amendment”), dated as of August 6, 2019, is entered into among BIO-REFERENCE LABORATORIES, INC., a New Jersey corporation (“Company”), the Subsidiary Borrowers party hereto (“Subsidiary Borrowers,” and together with Company, each a “Borrower” and, collectively, the “Borrowers”), the other Loan Parties |
|
| November 1, 2019 |
OPK / Opko Health, Inc. / HSIAO JANE PH D - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 7)* OPKO Health, Inc. (Name of Issuer) Common Shares, par value $0.01 per share (Title of Class of Securities) 68375N103 (CUSIP Number) Kate Inman General Counsel, Secretary OPKO Health, Inc. 4400 Biscayne Boulevard Miami, Florida 33137 Telephone: (305) 575-4100 (Name, |
|
| November 1, 2019 |
OPK / Opko Health, Inc. / FROST PHILLIP MD ET AL - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 19)* OPKO Health, Inc. (Name of Issuer) Common Shares, par value $0.01 per share (Title of Class of Securities) 68375N103 (CUSIP Number) Kate Inman General Counsel, Secretary OPKO Health, Inc. 4400 Biscayne Boulevard Miami, Florida 33137 Telephone: (305) 575-4100 (Name, |
|
| October 29, 2019 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2019 OPKO Health, Inc. |
|
| October 29, 2019 |
EX-1.1 Exhibit 1.1 EXECUTION VERSION 50,000,000 Shares OPKO Health, Inc. UNDERWRITING AGREEMENT October 24, 2019 JEFFERIES LLC PIPER JAFFRAY & CO. GUGGENHEIM SECURITIES, LLC as Representatives of the several Underwriters identified on Schedule A 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Introductory. OPKO Health, Inc., a Delaware corporation (the “Company”), proposes to iss |
|
| October 25, 2019 |
424B5 1 d822424d424b5.htm 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-229400 CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Amount of Securities to be Registered (1) Proposed Maximum Offering Price (2) Proposed Maximum Aggregate Offering Price Amount of Registration Fee(2) Common Stock, par value $0.01 per share 57,500,000.00 $1 |
|
| October 24, 2019 |
SUBJECT TO COMPLETION, DATED OCTOBER 24, 2019 Form 424(b)(5) Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. |
